<DOC>
	<DOC>NCT01487109</DOC>
	<brief_summary>This study is being conducted to evaluate the safety and efficacy of treatment with CTP-499 for 24 weeks in patients with chronic kidney disease, Type 2 diabetic nephropathy and who are currently receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin II receptor blocker (ARB).</brief_summary>
	<brief_title>A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients</brief_title>
	<detailed_description>There are two parts to this study, each part includes double-blind treatment with either CTP-499 or placebo. Part 1 will evaluate the safety and efficacy of treatment with CTP-499 twice daily for 24 weeks. Part 2 will evaluate the effects of longer term dosing for an additional 24 weeks. Following Part 2, patients will be allowed to participate in an Open Label extension with CTP-499 for a period of an additional 48 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Male or female 18 years or older Patient diagnosed with Type 2 diabetes mellitus and chronic kidney disease On a stable regimen of ACE inhibitors and/or ARB drugs for a minimum of 4 weeks Not expected to start dialysis for one year Patient has blood pressure less than or equal to 145/90 mm Hg Patient has UACR greater than or equal to 200 mg/g if male and 300 mg/g if female but not more than 5000 mg/g Patient has glycosylated hemoglobin A1c less than or equal to 10.5% Patient has concurrent condition such as uncontrolled inflammatory disease, acute infection or other unstable illnesses Patient has a history of allergy or sensitivity to pentoxifylline or methylxanthines Patient has acute, active and/or unstable renal impairment or has been hospitalized for acute renal failure within the previous year Patient has active malignancy or history of neoplastic disease Patient has a QTc interval greater than 450 milliseconds Patient has ALT or AST greater than 3 times the upper limit of normal or a potassium greater than or equal to 5.5mEq/L at screening Patient is breast feeding or pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>chronic kidney disease</keyword>
</DOC>